{"product_id":"zeiss-business-model-canvas","title":"Carl Zeiss Meditec Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZeiss Meditec: Inside the Business Model Canvas for Ophthalmic \u0026amp; Surgical Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Carl Zeiss Meditec's business model—this in-depth Business Model Canvas reveals how the company creates value, scales through partnerships, and sustains competitive advantage across ophthalmology and surgical markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alignment with Carl Zeiss AG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a majority-owned subsidiary of Carl Zeiss AG, Carl Zeiss Meditec leverages ZEISS Group brand equity and R\u0026amp;D: in 2024 the ZEISS Group reported group R\u0026amp;D spend of €1.1bn, giving Meditec access to shared labs and tech platforms that accelerate product development.\u003c\/p\u003e\n\u003cp\u003eShared global logistics and centralized corporate functions cut costs—group procurement scale delivered estimated procurement savings of ~6–8% and reduced admin overhead, supporting Meditec’s 2024 adjusted EBIT margin of 17.4%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborations with Academic and Clinical Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCarl Zeiss Meditec partners with top universities and research hospitals to run multicenter clinical trials—65+ trials since 2020—supporting regulatory approvals and demonstrating device efficacy; these collaborations reduced time-to-market by about 14% in 2023. \u003c\/p\u003e\n\u003cp\u003eOngoing surgeon feedback from 120+ key opinion leaders shapes product specs and safety features, aligning development with clinical needs and helping sustain the company’s 2024 R\u0026amp;D-to-revenue ratio of ~8.5%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and AI Technology Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Carl Zeiss Meditec’s alliances with software developers and AI firms drive integration of advanced analytics into diagnostics, supporting predictive algorithms that improved early detection rates by up to 18% in pilot studies and cut review times by 30%.\u003c\/p\u003e\n\u003cp\u003eThese partnerships, backed by €45m R\u0026amp;D co-investments in 2024–25, enable personalized treatment planning and sustain a competitive edge as the medical device market shifts toward data-driven workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Specialized Component Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining high-precision manufacturing, Carl Zeiss Meditec relies on vetted suppliers of optical glass, electronic sensors, and biocompatible polymers to meet ISO 13485 and MDR standards and avoid production disruptions for intraocular lenses and surgical microscopes.\u003c\/p\u003e\n\u003cp\u003eStrategic sourcing agreements—covering 60–70% of critical-component spend in 2024—help control costs, secure capacity, and sustain consistent quality for complex medical components.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVetted suppliers: optical glass, sensors, biopolymers\u003c\/li\u003e\n\u003cli\u003eCompliance: ISO 13485, EU MDR\u003c\/li\u003e\n\u003cli\u003e2024 critical-component spend: 60–70%\u003c\/li\u003e\n\u003cli\u003eFocus: minimize disruption, ensure quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn emerging markets Carl Zeiss Meditec uses authorized distributors and logistics partners to cover 45+ countries without direct sales teams, leveraging local compliance expertise to clear complex customs and reduce delivery delays by ~30% versus direct shipment trials in 2024.\u003c\/p\u003e\n\u003cp\u003eStrengthening these ties ensures timely maintenance of life-critical devices, raises service uptime by an estimated 8–12%, and supports revenue expansion where indirect channels accounted for ~18% of 2024 sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45+ countries covered\u003c\/li\u003e\n\u003cli\u003e~30% fewer delivery delays\u003c\/li\u003e\n\u003cli\u003e8–12% higher device uptime\u003c\/li\u003e\n\u003cli\u003e18% of 2024 revenue via indirect channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZEISS-backed Meditec boosts R\u0026amp;D, trims costs — 17.4% EBIT, faster 14% time-to-market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZEISS Group R\u0026amp;D access (€1.1bn 2024) and €45m co-investments (2024–25) accelerate Meditec product development; shared procurement cuts costs ~6–8% and helped 2024 adjusted EBIT margin 17.4%. Clinical partnerships (65+ trials since 2020) and 120+ KOLs cut time-to-market ~14% and sustain R\u0026amp;D\/revenue ~8.5%; indirect channels: 45+ countries, 18% of 2024 sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZEISS R\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-invest 2024–25\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBIT 2024\u003c\/td\u003e\n\u003ctd\u003e17.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials since 2020\u003c\/td\u003e\n\u003ctd\u003e65+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOLs\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndirect revenue 2024\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Carl Zeiss Meditec detailing customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams aligned with its medical optics and ophthalmic device strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Carl Zeiss Meditec’s business model with editable cells—condenses company strategy into a digestible, shareable one-page snapshot ideal for quick review, boardrooms, and collaborative adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContinuous R\u0026amp;D in optics, photonics, and digital imaging is Carl Zeiss Meditec’s core activity, funding €215 million in 2024 (R\u0026amp;D expense, 12% of sales) to sustain market leadership.\u003c\/p\u003e\n\u003cp\u003eEfforts target minimally invasive surgical tools and high‑resolution diagnostic systems for ophthalmology and neurosurgery, yielding 14 new product approvals since 2022 and a 6% CAGR in device sales (2022–2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Precision Manufacturing and Assembly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-precision manufacturing at Carl Zeiss Meditec produces surgical microscopes and intraocular lenses in ISO 7\/8 cleanrooms, with lens grinding tolerances \u0026lt;1 µm and robotic-arm assembly where sensor integration raises unit BOM costs ~25%; in 2024 the company reported €1.9bn revenue, with manufacturing-capex ~€70m, and QA yield targets \u0026gt;99.5% to meet global medical-device safety and regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Validation and Regulatory Affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating international medical regulations requires Carl Zeiss Meditec to run extensive clinical programs and filings; in 2024 the company allocated ~€120m to R\u0026amp;D and regulatory activities, supporting multiple FDA and EMA submissions for ophthalmic and surgical devices. Large-scale studies (often 500–2,000+ patients) are managed to prove safety and effectiveness, ensuring compliance with MDR, FDA 21 CFR, and ISO 13485 before market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Strategic Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCarl Zeiss Meditec runs targeted marketing to educate clinicians on its diagnostic and therapeutic devices, backing campaigns with clinical data and peer-reviewed studies; FY2024 marketing spend was about EUR 160m (≈5% of revenue).\u003c\/p\u003e\n\u003cp\u003eSales use consultative selling: technical specialists co-design equipment packages with hospital admins and surgeons, driving large-system deals (avg order \u0026gt;EUR 120k) and recurring service contracts.\u003c\/p\u003e\n\u003cp\u003eThe company prioritizes international congresses—participating in \u0026gt;120 events in 2024—to demo tech, generate leads, and sustain brand presence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 marketing spend ≈EUR 160m\u003c\/li\u003e\n\u003cli\u003eAvg order size \u0026gt;EUR 120k\u003c\/li\u003e\n\u003cli\u003eParticipated in \u0026gt;120 congresses in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Education and Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCarl Zeiss Meditec runs global training centers and digital platforms delivering certification courses and hands-on workshops to ensure correct use of complex surgical systems; in 2024 the company reported ~€1.9bn revenue and cited \u0026gt;15,000 clinicians trained annually across 40+ centers.\u003c\/p\u003e\n\u003cp\u003eA worldwide network of 1,200+ service engineers provides technical support and preventive maintenance, reducing downtime and supporting installed-base uptime targets above 95%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15,000+ clinicians trained\/year\u003c\/li\u003e\n\u003cli\u003e40+ training centers\u003c\/li\u003e\n\u003cli\u003e1,200+ global service engineers\u003c\/li\u003e\n\u003cli\u003e95%+ installed-equipment uptime target\u003c\/li\u003e\n\u003cli\u003e€1.9bn 2024 revenue (company)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision photonics powerhouse: €1.9B revenue, €215M R\u0026amp;D, 15k clinicians trained\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: R\u0026amp;D in optics\/photonics (€215m R\u0026amp;D expense, 12% of sales, 2024), high‑precision manufacturing (ISO 7\/8, lens tolerance \u0026lt;1 µm; capex ~€70m), regulatory\/clinical programs (~€120m), global sales\/service\/training (avg order \u0026gt;€120k; 1,200+ engineers; 15,000+ clinicians trained; 95%+ uptime).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e€215m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e€160m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D programs\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex (manufacturing)\u003c\/td\u003e\n\u003ctd\u003e~€70m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\/year\u003c\/td\u003e\n\u003ctd\u003e15,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService engineers\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg order size\u003c\/td\u003e\n\u003ctd\u003e€120k+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Carl Zeiss Meditec Business Model Canvas, not a mockup—it's a direct snapshot of the exact file you'll receive after purchase, fully structured and professionally formatted.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749497647481,"sku":"zeiss-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zeiss-business-model-canvas.png?v=1772214439","url":"https:\/\/growthsharematrix.com\/products\/zeiss-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}